AI-Driven Molecular Design for Antiviral Therapeutics

This contract focuses on the development of advanced AI and machine learning platforms aimed at creating and optimizing new small-molecule inhibitors specifically targeting filoviruses. The work involves the use of generative chemistry techniques combined with docking simulations and binding affinity prediction to enhance the discovery process of antiviral therapeutics. The goal is to leverage computational methods to streamline the identification of effective compounds that can inhibit virus activity. Issued as a subcontract under NAICS code 541715, the contract is managed by the Department of Health and Human Services through BARDA and associated entities. The solicitation was posted in May 2026, with responses due by mid-July 2026. While detailed organizational and location information is not specified, the initiative clearly supports government efforts to address biosecurity and public health challenges posed by filoviruses through cutting-edge molecular design technologies.